Results 171 to 180 of about 268,545 (217)

Toxicology of depot medroxyprogesterone acetate

Contraception, 1994
Depo-Provera (depot-medroxyprogesterone acetate or DMPA), administered either subcutaneously or intramuscularly, has undergone a thorough toxicological evaluation in a number of animal species. DMPA has been tested in short- and long-term toxicity studies in rodents, rabbits, and monkeys.
openaire   +2 more sources

The Response of the Bitch to Treatment with Medroxyprogesterone Acetate

Journal of Small Animal Practice, 1967
Abstract— —Medroxyprogesterone acetate (M.A.P.) was administered to three groups of bitches as follows: Eighty‐six bitches received a total of 166 injections of M.A.P. to prevent or suppress oestrus. This procedure was entirely successful in 83 bitches (96.5 per cent) and partially successful or unsuccessful in the remaining 3 bitches.
A R, Withers, J C, Whitney
openaire   +2 more sources

The Cushing Syndrome Induced by Medroxyprogesterone Acetate

Annals of Internal Medicine, 1989
Excerpt The Cushing syndrome is a constellation of abnormalities resulting from chronic excess glucocorticoid activity (1).
K, Siminoski, P, Goss, D J, Drucker
openaire   +2 more sources

CONTRACEPTIVE AND ENDOMETRIAL EFFECTS OF MEDROXYPROGESTERONE ACETATE

Obstetrical & Gynecological Survey, 1969
Present means of contraception are not satisfactory for all women. This study reports on the contraception efficacy and menstrual abnormalities of medroxyprogesterone acetate (Depo-Provera), which was given in an intramuscular dose of 150 mg. every 3 months for 1 year.
openaire   +2 more sources

GLC Determination of Medroxyprogesterone Acetate in Plasma

Journal of Pharmaceutical Sciences, 1974
To study the absorption, metabolism, and excretion of medroxyprogesterone acetate in animals and man, a method was developed for measurement of the intact drug in plasma based on: (a) cyclohexane extraction of the specimen, (b) formation of the 3-enol heptafluorobutyrate ester, and (c) quantification via GLC using an electron-capture detector.
D G, Kaiser, R G, Carlson, K T, Kirton
openaire   +2 more sources

UNSUCCESSFUL TREATMENT OF ACROMEGALY WITH MEDROXYPROGESTERONE ACETATE

Acta Endocrinologica, 1974
ABSTRACT Six patients with active acromegaly were treated with medroxyprogesterone acetate (MPA) in a dose of 10 mg four times a day for periods of two weeks to six months. Basal growth hormone (GH) levels, oral glucose tolerance tests, insulin tolerance tests, and arginine stimulation tests were obtained before and after one week, one month ...
R L, Atkinson, R C, Dimond, W J, Howard, J M, Earll   +3 more
openaire   +2 more sources

Treatment of Breast Cancer with Medroxyprogesterone Acetate

Annals of Internal Medicine, 1968
The prolonged administration of large doses of medroxyprogesterone acetate (MPA) in the treatment of patients with disseminated breast cancer was studied. The patients consisted of 17 postmenopausal women previously treated with 1 or more hormones (group I) 17 women (oophorectomized or postnatural menopause) who had received MPA prior to the study ...
F M, Muggia, P A, Cassieth, M, Ochoa, F A, Flatow, A, Gellhorn, G A, Hyman   +5 more
openaire   +2 more sources

Augmentation of exercise ventilation by medroxyprogesterone acetate

Clinical Physiology, 1982
Summary. The influence of medroxyprogesterone acetate (MPA) on exercise performance was studied in a double‐blind cross‐over trial using six normal males to compare the exercise performance changes to those observed in a previous study of exercise responses of female subjects during the follicular and luteal phase of the menstrual cycle.
H T, Robertson, R B, Schoene, D J, Pierson   +2 more
openaire   +2 more sources

The Contraceptive Use of Depot Medroxyprogesterone Acetate

Clinical Obstetrics and Gynecology, 1995
Depot medroxyprogesterone acetate (DMPA) was the first popular long-acting progestogen-only contraceptive and is used by more than nine million women worldwide. It is one of the most convenient and effective yet readily reversible methods of contraception.
M, Hickey, I, Fraser
openaire   +2 more sources

The metabolic fate of medroxyprogesterone acetate in the baboon

Journal of Steroid Biochemistry, 1976
Abstract The metabolic fate of medroxyprogesterone acetate (6α-methyl-17α-acetoxyprogesterone, MAP) was studied in intact baboons and in those with bile fistulas. The steroid moiety was labeled with 3 H at positions 1 and 2 and the 17α-acetate with 14 C, thus affording the opportunity to ascertain the loss of the 17-acetoxy group and the fate of ...
M, Ishihara, Y, Kirdani, Y, Osawa, A A, Sandberg   +3 more
openaire   +2 more sources